Increased Tc17 cell levels and imbalance of naïve/effector immune response in Parkinson’s disease patients in a two-year follow-up: a case control study

• Main Authors: Diana D. Álvarez-Luquín, Adrián Guevara-Salinas, Asiel Arce-Sillas, Raquel Espinosa-Cárdenas, Jaquelín Leyva-Hernández, Esteban U. Montes-Moratilla, Laura Adalid-Peralta
• Format: Article
• Language: English
• Published: BMC 2021-09-01
• Series: Journal of Translational Medicine
• Subjects: Immune response; Parkinson’s disease; Untreated patients; Immunophenotyping; Flow cytometry
• Online Access: https://doi.org/10.1186/s12967-021-03055-2

Abstract Background Neuroinflammation has been proved to play a role in dopaminergic neuronal death in Parkinson’s disease (PD). This link highlights the relevance of the immune response in the progression of the disease. However, little is known about the impact of peripheral immune response on the disease. This study is aimed to evaluate how immune cell populations change in untreated PD patients followed-up for 2 years. Methods Thirty-two patients with no previous treatment (PD-0 yr) and twenty-two healthy subjects (controls) were included in the study. PD patients were sampled 1 and 2 years after the start of the treatment. CD4 T cells (naïve/central memory, effector, and activated), CD8 T cells (activated, central memory, effector memory, NKT, Tc1, Tc2, and Tc17), and B cells (activated, plasma, and Lip-AP) were characterized by flow cytometry. Results We observed decreased levels of naïve/central memory CD4 and CD8 T cells, Tc1, Tc2, NKT, and plasma cells, and increased levels of effector T cells, activated T cells, and Tc17. Conclusions PD patients treated for 2 years showed an imbalance in the naive/effector immune response. Naïve and effector cell levels were associated with clinical deterioration. These populations are also correlated to aging. On the other hand, higher Tc17 levels suggest an increased inflammatory response, which may impact the progression of the disease. Our results highlight the relevant effect of treatment on the immune response, which could improve our management of the disease.